hotspot -WSS

hotspot

author：hotspot 2025-09-27 13:03:58 - browse：99

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： States increasingly look to regulate hospital facility fees

knowledge

WSS

New warning issued for rebooking air travel after delays, cancellations

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Class action alleges UnitedHealth concealed DOJ probe

Why the Crimean Bridge is key to Russia's war in Ukraine

Has Bernie Sanders reached the limit of his pharma bullying effort?

entertainment

hotspot

Wikipedia

Virginia high school admissions case could be legal follow

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Walensky prepares to leave CDC — and Congress — behind

Can gargling with Listerine treat gonorrhea of the mouth?

Duchenne breakthrough therapy leaves behind pioneering families

Crowdfunding for medical bills sidesteps core problem, author says

Moonlake's readout produced a cash windfall. Risks remain

Novel spinal cord stimulator treats paralysis without surgery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

hotspot

BIO to announce reorganization, senior leaders expected to depart

TikTok cracks down on users posting about weight loss drugs

BIO to announce reorganization, senior leaders expected to depart

How dance can help health care workers heal from trauma

Trump got a 'target letter.' What is one and what does it mean?

How dance can help health care workers heal from trauma

entertainment

leisure time

knowledge

leisure time